AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- The Phase 1b study of PTX-100 has successfully met its primary endpoints, demonstrating excellent safety.
- The study demonstrated preliminary efficacy, exceeding that expected from standard of care, in patients with relapsed and refractory T-cell lymphomas (r/r TCL)
- PTX plans to commence Phase 2 study in 2024.
Prescient Therapeutics Limited (ASX: PTX) has shared encouraging PTX-100 Phase 1b study results. The findings were showcased at the annual meeting of the American Society of Hematology (ASH) in California.
The study is designed to assess the safety, pharmacodynamics (PD), pharmacokinetics (PK) and preliminary efficacy profile of PTX-100 in patients with advanced malignancies. The trial focused on patients with r/r TCL.
The data surpassed the company’s expectations from both the safety and preliminary efficacy perspectives.
The company informed that the recruitment for Phase 1b study has been concluded, although multiple patients remain on study.
Presently, the company is working towards a Phase 2 trial in r/r TCL, scheduled in mid-2024. The development is expected to be a significant catalyst for the company.
PTX shares traded at AU$0.070 apiece at the time of writing on 11 December 2023.
